Mark John Millan

Mark John Millan's AcademicInfluence.com Rankings

Mark John Millan

Psychology

#1762

World Rank

#2098

Historical Rank

Cognitive Psychology

#118

World Rank

#122

Historical Rank

Social Psychology

#151

World Rank

#161

Historical Rank

psychology Degrees

Download Badge

Psychology

Mark John Millan's Degrees

PhD Psychology Stanford University
Masters Psychology Stanford University
Bachelors Psychology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Psychology 2025

Why Is Mark John Millan Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Mark John Millan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The induction of pain: an integrative review (1999) (1740)
Descending control of pain (2002) (1176)
The neurobiology and control of anxious states (2003) (935)
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy (2012) (934)
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. (2006) (521)
The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways (2003) (515)
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes (2002) (452)
Altering the course of schizophrenia: progress and perspectives (2016) (390)
Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat (2000) (331)
Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. (2000) (308)
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development (2010) (307)
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing (2018) (300)
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing (2020) (294)
Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo (1998) (293)
Multiple opioid systems and pain (1986) (287)
κ-Opioid receptors and analgesia (1990) (285)
(1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. (1995) (267)
The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. (2004) (266)
Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. (2008) (264)
Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment (2014) (261)
Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. (2005) (261)
Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents (2000) (246)
Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade (2005) (246)
Dopamine D3 receptor antagonists as therapeutic agents. (2005) (232)
N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives (2005) (223)
Deconstructing Vulnerability for Psychosis: Meta-Analysis of Environmental Risk Factors for Psychosis in Subjects at Ultra High-Risk (2017) (223)
Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention. (2020) (213)
Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release (1998) (207)
Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain (2006) (206)
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a []GTPγS binding study (1998) (205)
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy (2013) (200)
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes (2002) (182)
Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs (2011) (177)
Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats (1999) (172)
Agonist and antagonist actions of yohimbine as compared to fluparoxan at α2‐adrenergic receptors (AR)s, serotonin (5‐HT)1A, 5‐HT1B, 5‐HT1D and dopamine D2 and D3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states (2000) (171)
Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex. (2012) (170)
Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity (2007) (168)
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and α1/α2-Adrenoceptor (2002) (162)
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus (2009) (159)
Multiple alpha-2 adrenergic receptor subtypes. II. Evidence for a role of rat R alpha-2A adrenergic receptors in the control of nociception, motor behavior and hippocampal synthesis of noradrenaline. (1994) (144)
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. (2001) (143)
5-HT6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia (2012) (142)
Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex (2012) (141)
Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists. (1993) (141)
Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. (1994) (135)
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. (1998) (135)
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. (1995) (133)
Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank (2015) (130)
Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. (1995) (128)
Selective blockade of dopamine D3 versus D2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis (2007) (127)
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. (2000) (127)
S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. (2001) (126)
S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models (2008) (125)
Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties (2014) (123)
The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines (2003) (122)
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. (2000) (122)
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. (1995) (122)
The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors (2001) (120)
Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake A pharmacological characterization of diverse classes of antidepressant agents (2002) (118)
Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders (2015) (116)
5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. (1997) (115)
Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. (2002) (114)
Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. (1999) (114)
Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors (1996) (112)
Actions of α2 adrenoceptor ligands at α2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for α2A adrenoceptors (1998) (110)
Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of α2-adrenergic receptors underlie its actions (1999) (107)
Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5‐HT)1A receptors: WAY 100,635‐reversible actions of the highly selective ligands, flesinoxan and S 15535 (1998) (107)
Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer’s disease: An integrative review (2017) (107)
Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. (2007) (106)
Antinociceptive profiles of non-peptidergic neurokinin1 and neurokinin2 receptor antagonists: a comparison to other classes of antinociceptive agent (1995) (104)
The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats (2004) (103)
Multiple alpha 2 adrenergic receptor subtypes. I. Comparison of [3H]RX821002-labeled rat R alpha-2A adrenergic receptors in cerebral cortex to human H alpha2A adrenergic receptor and other populations of alpha-2 adrenergic subtypes. (1994) (103)
Inverse Agonist and Neutral Antagonist Actions of Antidepressants at Recombinant and Native 5-Hydroxytryptamine2C Receptors: Differential Modulation of Cell Surface Expression and Signal Transduction (2008) (101)
Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex (2007) (100)
Anxiolytic Properties of the Selective, Non-peptidergic CRF1 Antagonists, CP154,526 and DMP695: A Comparison to Other Classes of Anxiolytic Agent (2001) (99)
Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: The CNTRICS initiative (2013) (98)
Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats. (1997) (96)
Agonist and Inverse Agonist Efficacy at Human Recombinant Serotonin 5-HT1A Receptors as a Function of Receptor:G-protein Stoichiometry (1997) (94)
G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study. (1999) (94)
Expanding the repertoire of L-DOPA’s actions: A comprehensive review of its functional neurochemistry (2017) (90)
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. (1998) (90)
S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. (2000) (89)
Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling (2018) (88)
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development (2010) (88)
Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth. (2014) (87)
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease (2009) (86)
N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. (2002) (85)
Inhibition of the constitutive activity of human 5‐HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635 (1997) (85)
Serotonin and pain: evidence that activation of 5-HT1A receptors does not elicit antinociception against noxious thermal, mechanical and chemical stimuli in mice (1994) (84)
Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole (2003) (83)
Convergence of Melatonin and Serotonin (5-HT) Signaling at MT2/5-HT2C Receptor Heteromers* (2015) (82)
Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols (2002) (81)
Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists. (1994) (80)
Genetic Deletion of Trace Amine 1 Receptors Reveals Their Role in Auto-Inhibiting the Actions of Ecstasy (MDMA) (2011) (79)
Stress and endogenous opioid peptides: a review. (1981) (79)
Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats. (1995) (78)
The Role of Descending Noradrenergic and Serotoninergic Pathways in the Modulation of Nociception: Focus on Receptor Multiplicity (1997) (78)
Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole (2003) (77)
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. (1998) (77)
Modulation of Dialysate Levels of Dopamine, Noradrenaline, and Serotonin (5-HT) in the Frontal Cortex of Freely-Moving Rats by (-)-Pindolol Alone and in Association with 5-HT Reuptake Inhibitors: Comparative Roles of β-Adrenergic, 5-HT1A, and 5-HT1B Receptors (1999) (77)
The Serotonin1A Receptor Partial Agonist S15535 [4-(Benzodioxan-5-yl)1-(indan-2-yl)piperazine] Enhances Cholinergic Transmission and Cognitive Function in Rodents: A Combined Neurochemical and Behavioral Analysis (2004) (75)
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. (1997) (75)
Human Pluripotent Stem Cell-derived Cortical Neurons for High Throughput Medication Screening in Autism: A Proof of Concept Study in SHANK3 Haploinsufficiency Syndrome (2016) (73)
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride. (1998) (73)
Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. (1995) (72)
Buspirone Enhances Duloxetine‐ and Fluoxetine‐Induced Increases in Dialysate Levels of Dopamine and Noradrenaline, but Not Serotonin, in the Frontal Cortex of Freely Moving Rats (1997) (71)
Sexual side effects of serotonergic antidepressants: Mediated by inhibition of serotonin on central dopamine release? (2014) (70)
Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: Similar actions of D1 receptor agonists, but not of D2 antagonists (2009) (70)
Selective blockade of neurokinin (NK)1 receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats (2001) (70)
S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects (2008) (70)
Signaling Pathways Leading to Phosphorylation of Akt and GSK-3β by Activation of Cloned Human and Rat Cerebral D2 and D3 Receptors (2011) (69)
Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors. (1997) (69)
Agonist and Antagonist Actions of (-)Pindolol at Recombinant, Human Serotonin1A (5-HT1A) Receptors (1998) (68)
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. (1998) (66)
From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. (2010) (66)
Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. (2010) (65)
Pro- and antinociceptive actions of serotonin (5-HT)1A agonists and antagonists in rodents: relationship to algesiometric paradigm (1995) (65)
Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance. (2009) (64)
Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling. (2002) (64)
Chemically-diverse ligands at the glycine B site coupled to N-methyl-d-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice (1994) (64)
The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines. (2003) (63)
Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats byα1 as compared toα2 agonists and antagonists (1991) (62)
On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. (2014) (62)
Nicotine-Induced Structural Plasticity in Mesencephalic Dopaminergic Neurons Is Mediated by Dopamine D3 Receptors and Akt-mTORC1 Signaling (2013) (62)
Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297. (1994) (62)
Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by α2-autoreceptors (2004) (61)
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. (2000) (60)
[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. (1997) (60)
Blockade of dopamine D₃ but not D₂ receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. (2012) (60)
Serotonin (5-HT) and pain: A reappraisal of its role in the light of receptor multiplicity (1995) (59)
The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats (2000) (59)
The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. (2010) (59)
The Tetrahydroisoquinoline Derivative SB269,652 Is an Allosteric Antagonist at Dopamine D3 and D2 Receptors (2010) (58)
Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats. (2007) (58)
Clozapine inhibits serotoninergic transmission by an action at alpha 1-adrenoceptors not at 5-HT1A receptors. (1994) (57)
Kappa-opioid receptors and analgesia. (1990) (57)
5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity. (1991) (57)
Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist. (1999) (57)
MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues. (2011) (57)
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors (2008) (56)
Association of Changes in Norepinephrine and Serotonin Transporter Expression with the Long-Term Behavioral Effects of Antidepressant Drugs (2009) (55)
S 15535: a highly selective benzodioxopiperazine 5-HT1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively. (1993) (55)
Vasopressin and oxytocin in the rat spinal cord: analysis of their role in the control of nociception (1984) (54)
S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. (1994) (54)
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: III. Actions in Models of Potential Antidepressive and Anxiolytic Activity in Comparison with Ropinirole (2004) (54)
Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy (1997) (53)
The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity? (2014) (52)
The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats (2009) (51)
The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors. (2011) (50)
Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets (2016) (50)
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole (2004) (50)
Pre‐synaptic dopamine D3 receptor mediates cocaine‐induced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways (2012) (49)
Tetracyclic analogues of [+]-S 14297: Synthesis and determination of affinity and selectivity at cloned human dopamine D3 vs D2 receptors (1997) (49)
Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptormediated phosphoinositide (PI) turnover by clozapine in the rat: A comparison to other antipsychotics (1994) (49)
Opioid systems in the response to inflammatory pain: Sustained blockade suggests role of κ- but not μ-opioid receptors in the modulation of nociception, behaviour and pathology (1991) (49)
S 14506: A novel, potent, high‐efficacy 5‐HT1A agonist and potential anxiolytic agent (1992) (49)
Functional Homomers and Heteromers of Dopamine D2L and D3 Receptors Co-exist at the Cell Surface (2012) (49)
Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine (2013) (48)
S 15535 and WAY 100,635 antagonise 5-HT-stimulated [35S]GTP gamma S binding at cloned human 5-HT1A receptors. (1996) (47)
Aversive properties of naloxone in non-dependent (naive) rats may involve blockade of central β-endorphin (2004) (47)
Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythms (2007) (47)
Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors. (1998) (46)
Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors (2006) (46)
Evidence that an α2A-adrenoceptor subtype mediates antinociception in mice (1992) (45)
Piribedil Enhances Frontocortical and Hippocampal Release of Acetylcholine in Freely Moving Rats by Blockade of α2A-Adrenoceptors: A Dialysis Comparison to Talipexole and Quinelorane in the Absence of Acetylcholinesterase Inhibitors (2003) (45)
Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling (2018) (45)
S18327 (1-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at α1- and α2-Adrenergic Receptors: II. Functional Profile and a Multiparametric Comparison with Haloperidol, Clozapine, and 11 Othe (2000) (45)
Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. (1997) (44)
Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138. (2008) (44)
Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, l-DOPA Responsivity, and Glutamatergic Neurotransmission (2015) (44)
Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser280 by Hallucinogenic versus Nonhallucinogenic Agonists* (2014) (44)
5-HT1A receptors and the tail-flick response. IV. Spinally localized 5-HT1A receptors postsynaptic to serotoninergic neurones mediate spontaneous tail-flicks in the rat. (1993) (43)
S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors. (1992) (43)
Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake (2015) (43)
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. (2001) (42)
Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry. (2000) (42)
5-hydroxytryptamine (HT)1A receptors and the tail-flick response. II. High efficacy 5-HT1A agonists attenuate morphine-induced antinociception in mice in a competitive-like manner. (1991) (42)
Involvement of dopamine D2/D3 receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells (2004) (41)
Inverse Agonist Properties of Antipsychotic Agents at Cloned, Human (h) Serotonin (5-HT)1B and h5-HT1D Receptors (2001) (41)
WAY 100,135 and (-)-tertatolol act as antagonists at both 5-HT1A autoreceptors and postsynaptic 5-HT1A receptors in vivo. (1993) (41)
Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes (2003) (41)
Dopamine D1 receptor coupling to Gs/olf and Gq in rat striatum and cortex: A scintillation proximity assay (SPA)/antibody-capture characterization of benzazepine agonists (2007) (41)
Anxiolytic properties of opiates and endogenous opioid peptides and their relationship to the actions of benzodiazepines. (1981) (40)
Evidence for functional trace amine associated receptor-1 in normal and malignant B cells. (2012) (40)
Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N‐desmethylclozapine and preclamol at dopamine D2L receptors are modified by co‐transfection of D3 receptors: potential role of heterodimer formation (2007) (40)
(+)-HA 966, a partial agonist at the glycine site coupled to NMDA receptors, blocks formalin-induced pain in mice. (1993) (39)
Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)1A receptors (2002) (39)
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity. (1997) (39)
Serotonin1A autoreceptor activation by S 15535 enhances circadian activity rhythms in hamsters: Evaluation of potential interactions with serotonin2A and serotonin2C receptors (2006) (37)
S33138 [N-[4-[2-[(3aS,9bR)-8-Cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral Characterization in Vivo (2008) (37)
The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. (1997) (37)
S-16924, a novel, potential antipsychotic with marked serotonin1A agonist properties. IV. A drug discrimination comparison with clozapine. (1999) (37)
Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties. (2001) (36)
A drug discrimination analysis of the actions of novel serotonin1A receptor ligands in the rat using the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin. (1995) (36)
S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5‐HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine (1999) (36)
α1-Adrenoceptors Mediate Dihydroxyphenylalanine-Induced Activity in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaques (2009) (36)
Differential modulation of efficiency in a food-rewarded "differential reinforcement of low-rate" 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors (2002) (35)
Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s. (2008) (35)
WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex. (1998) (35)
Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation (2015) (35)
The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells (2019) (34)
Endorphinergic systems and the response to stress. (1981) (34)
Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra (2001) (34)
Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. (2004) (34)
Transient and rapid activation of Akt/GSK‐3β and mTORC1 signaling by D3 dopamine receptor stimulation in dorsal striatum and nucleus accumbens (2013) (33)
European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP) (2019) (33)
The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders (2016) (32)
8-OH-DPAT-induced Spontaneous Tail-flicks in the Rat are Facilitated by the Selective Serotonin (5-HT)2C Agonist, RO 60-0175: Blockade of its Actions by the Novel 5-HT2C Receptor Antagonist SB 206,553 (1997) (32)
The selective neurokinin (NK)1 antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study (2002) (32)
CRF1 Not Glucocorticoid Receptors Mediate Prepulse Inhibition Deficits in Mice Overexpressing CRF (2008) (32)
The CRF1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized rats. (2003) (31)
5-HT2C receptors are involved in the discriminative stimulus effects of citalopram in rats (1999) (31)
S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol. (1999) (31)
Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: Definition of its binding profile using agonists, antagonists and inverse agonists (1998) (31)
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture (2009) (31)
The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect l-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats (2010) (31)
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole (2004) (31)
5-HT1A-receptor over-expressing mice: Genotype and sex dependent responses to antidepressants in the forced swim-test (2011) (31)
Involvement of β-endorphin and μ-opioid receptors in mediating the aversive effect of lithium in the rat (1988) (30)
Comparison of hippocampal G protein activation by 5-HT1A receptor agonists and the atypical antipsychotics clozapine and S16924 (2003) (30)
S 33084 , a Novel , Potent , Selective , and Competitive Antagonist at Dopamine D 3-Receptors : I . Receptorial , Electrophysiological and Neurochemical Profile Compared with GR 218 , 231 and L 741 , 626 (2000) (30)
S 33084 , a Novel , Potent , Selective , and Competitive Antagonist at Dopamine D 3-Receptors : II . Functional and Behavioral Profile Compared with GR 218 , 231 and L 741 , 626 (2000) (29)
S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization (2012) (29)
Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson's disease. (2013) (28)
Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia. (1995) (28)
Evidence that an alpha 2A-adrenoceptor subtype mediates antinociception in mice. (1992) (27)
Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine (2003) (27)
Long-term blockade of μ-opioid receptors suggests a role in control of ingestive behaviour, body weight and core temperature in the rat (1988) (27)
Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: A comparison to other agents (2008) (27)
5-hydroxytryptamine (HT)1A receptors and the tail-flick response. III. Structurally diverse 5-HT1A partial agonists attenuate mu- but not kappa-opioid antinociception in mice and rats. (1991) (27)
α2 Receptors mediate the antinociceptive action of 8-OH-DPAT in the hot-plate test in mice (1991) (27)
Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation. (2001) (27)
Differential modulation by GTPγS of agonist and inverse agonist binding to h5‐HT1A receptors revealed by [3H]‐WAY100,635 (2001) (26)
Ligand modulation of [ 35S]GTP?S binding at human a 2A, a 2B and a 2C adrenoceptors (2002) (26)
Attenuation of opioid induced antinociception by 5-HT1A partial agonists in the rat (1990) (26)
The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats. (2008) (25)
Characterization of potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazines. (1995) (25)
Constitutive activity at serotonin 5-HT1D receptors: detection by homologous GTPγS versus [35S]-GTPγS binding isotherms (2001) (25)
The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats (2010) (25)
Local inactivation of Gpr88 in the nucleus accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in rats (2014) (25)
Influence of positive allosteric modulators on GABAB receptor coupling in rat brain: a scintillation proximity assay characterisation of G protein subtypes (2008) (25)
Improvement in the selectivity and metabolic stability of the serotonin 5-HT1A ligand, S 15535: A series of cis- and trans-2-(arylcycloalkylamine) 1-indanols (2002) (24)
Neurokinin1 Antagonists Potentiate Antidepressant Properties of Serotonin Reuptake Inhibitors, Yet Blunt Their Anxiogenic Actions: A Neurochemical, Electrophysiological, and Behavioral Characterization (2009) (24)
Bidirectional modulation of classical fear conditioning in mice by 5-HT1A receptor ligands with contrasting intrinsic activities (2009) (24)
Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006. (2012) (24)
The potent activity of the 5-HT1A receptor agonists, S 14506 and S 14671, in the rat forced swim test is blocked by novel 5-HT1A receptor antagonists. (1994) (24)
Binding profile of the novel 5-HT1B/1D receptor antagonist, [3H]GR 125,743, in guinea-pig brain: a comparison with [3H]5-carboxamidotryptamine. (1997) (23)
The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors. (2000) (23)
Naloxone attenuates the anxiolytic action of diazepam in man. (1982) (23)
Quantification of extracellular levels of corticosterone in the basolateral amygdaloid complex of freely-moving rats: A dialysis study of circadian variation and stress-induced modulation (2012) (23)
S 14506: novel receptor coupling at 5-HT1A receptors (2001) (23)
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture (2009) (23)
Trace amines depress D2‐autoreceptor‐mediated responses on midbrain dopaminergic cells (2010) (23)
5-HT1A receptors and the tail-flick response. VI. Intrinsic alpha 1A-adrenoceptor antagonist properties can mask the actions of 5-HT1A receptor agonists in the spontaneous tail-flick paradigm. (1994) (22)
Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors (1999) (22)
Inhibitory and facilitory actions of isocyanine derivatives at human and rat organic cation transporters 1, 2 and 3: a comparison to human alpha 1- and alpha 2-adrenoceptor subtypes. (2010) (22)
The glycine B receptor partial agonist, (+)-HA966, enhances induction of antinociception by RP 67580 and CP-99,994. (1994) (22)
h5‐HT1B receptor‐mediated constitutive Gαi3‐protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5‐HT (2003) (21)
Potentiation of fluoxetine-induced penile erections by combined blockade of 5-HT1A and 5-HT1B receptors. (1997) (21)
Apparent hyperalgesic action of the 5-HT1A agonist, 8-OH-DPAT, in the rat reflects induction of spontaneous tail-flicks (1989) (20)
DRD3 (dopamine receptor D3) but not DRD2 activates autophagy through MTORC1 inhibition preserving protein synthesis (2020) (20)
60 years of advances in neuropsychopharmacology for improving brain health, renewed hope for progress (2015) (20)
Molecular adaptation to chronic antidepressant treatment: evidence for a more rapid response to the novel α₂-adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, compared to the SNRI, venlafaxine. (2012) (19)
Dual-acting agents for improving cognition and real-world function in Alzheimer’s disease: Focus on 5-HT6 and D3 receptors as hubs (2020) (19)
Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice (2012) (19)
CRF₂ receptor-deficiency reduces recognition memory deficits and vulnerability to stress induced by cocaine withdrawal. (2014) (19)
Characterisation of Gs activation by dopamine D1 receptors using an antibody capture assay: antagonist properties of clozapine. (2004) (19)
The Discovery and Development of Pharmacotherapy for Psychiatric Disorders: A Critical Survey of Animal and Translational Models and Perspectives for Their Improvement (2008) (19)
Down-regulation of rat β-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [3H]CGP-12177 binding reveals rapid (24 hour) modulation (1996) (19)
Lesions of the hypothalamic arcuate nucleus modify discrete brain and pituitary pools of dynorphin in addition to β-endorphin in the rat (1984) (19)
5-HT1A receptors and the tail-flick response. V. Opposite modulation of 5-HT1A receptor-induced spontaneous tail-flicks by alpha 1A- as compared with alpha 2D-adrenoceptors in rat lumbar spinal cord. (1994) (19)
The Selective Serotonin2A Receptor Antagonist, MDL100,907, Elicits a Specific Interoceptive Cue in Rats (2002) (18)
Glutamatergic and dopaminergic modulation of cortico-striatal circuits probed by dynamic calcium imaging of networks reconstructed in microfluidic chips (2018) (18)
The benzodiazepine diazepam demonstrates the usefulness of Syrian hamsters as a model for anxiety testing: Evaluation of other classes of anxiolytics in comparison to diazepam (2011) (18)
Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats (2001) (18)
Simultaneous quantification of d- vs. l-serine, taurine, kynurenate, phosphoethanolamine and diverse amino acids in frontocortical dialysates of freely-moving rats: Differential modulation by N-methyl-d-aspartate (NMDA) and other pharmacological agents (2011) (17)
[3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors (2000) (17)
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile. (2000) (17)
Positive and negative modulation of circadian activity rhythms by mGluR5 and mGluR2/3 metabotropic glutamate receptors (2011) (17)
Methylenedioxymethamphetamine induces spontaneous tail-flicks in the rat via 5-HT1A receptors. (1991) (17)
Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management (2020) (17)
Agonist action at 5-HT1C receptors facilitates 5-HT1A receptor-mediated spontaneous tail-flicks in the rat. (1990) (17)
Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats by alpha 1 as compared to alpha 2 agonists and antagonists. (1991) (17)
Actions at sites other than D3 receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats (2006) (16)
Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors (2007) (16)
The role of 5-HT1A autoreceptors and α 1-adrenoceptors in the modulation of 5-HT release—III. Clozapine and the novel putative antipsychotic S 16924 (1998) (16)
A Molecular Basis for Selective Antagonist Destabilization of Dopamine D3 Receptor Quaternary Organization (2017) (16)
Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: Parallel observations from co-transfected human and native cerebral receptors (2011) (15)
Agonist properties of pindolol at h5-HT1A receptors coupled to mitogen-activated protein kinase. (2001) (15)
Discriminative stimulus properties of the selective and highly potent α2-adrenoceptor agonist, S18616, in rats: Mediation by the α2A subtype, and blockade by the atypical antidepressants, mirtazapine and mianserin (2006) (15)
S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: A comparison to aprepitant (MK869) and paroxetine (2010) (15)
Specific labelling of serotonin 5-HT1B receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743 A pharmacological characterization (2002) (15)
Differential influence of selective 5-HT5A vs 5-HT1A, 5-HT1B, or 5-HT2C receptor blockade upon light-induced phase shifts in circadian activity rhythms: Interaction studies with citalopram (2009) (15)
The 5HT(1A) receptor ligand, S15535, antagonises G-protein activation: a [35S]GTPgammaS and [3H]S15535 autoradiography study. (1999) (14)
Blockade of NMDA receptors in the nucleus accumbens elicits spontaneous tail-flicks in rats. (2000) (14)
Electrophysiologic characterization of the antinociceptive actions of S18616, a novel and potent alpha 2-adrenoceptor agonist, after acute and persistent pain states. (2002) (14)
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D 2 -Like Receptor and (cid:1) 1 / (cid:1) 2 -Adrenoceptor (2002) (14)
S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: I. A Mechanistic Characterization (2012) (13)
The influence of sustained opioid receptor blockade in a model of long-term, localized inflammatory pain in rats (1990) (13)
Acute administration of the novel serotonin and noradrenaline reuptake inhibitor, S33005, markedly modifies sleep–wake cycle architecture in the rat (2005) (13)
Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands. (1999) (12)
Discriminative stimulus properties of the “atypical” antidepressant, mirtazapine, in rats: a pharmacological characterization (2009) (12)
Involvement of 5-HT1A receptors in the anxiolytic action of S 14671 in the pigeon conflict test (1995) (12)
The corticotropin-releasing factor (CRF)1 receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms (2006) (12)
Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male rat (1998) (11)
Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats (2001) (11)
α2-Adrenergic Mechanisms of Analgesia: Strategies for Improving Their Therapeutic Window and Identification of the Novel, Potent α2-Adrenergic Receptor Agonist, S 18616 (1997) (11)
Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or β-Phenylethylamine (2018) (11)
[3H](+)S 14297: A novel, selective radioligand at cloned human dopamine D3 receptors (1995) (11)
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors (2006) (11)
Design, Synthesis, and Optimization of Balanced Dual NK1/NK3 Receptor Antagonists. (2014) (11)
The role of the mediobasal arcuate hypothalamus in relation to opioid systems in the control of ingestive behaviour in the rat (1986) (11)
Diverse effects of 5-HT2C receptor blocking agents on c-Fos expression in the rat basal ganglia. (2012) (11)
An innovative method for rapid characterisation of phospholipase C activity: SB242,084 competitively antagonises 5-HT2C receptor-mediated [3H]phosphatidylinositol depletion (2000) (11)
(−)-Pindolol increases dialysate concentrations of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely-moving rats (1999) (10)
Lifelong disturbance of serotonin transporter functioning results in fear learning deficits: Reversal by blockade of CRF1 receptors (2015) (10)
Lifelong CRF overproduction is associated with altered gene expression and sensitivity of discrete GABAA and mGlu receptor subtypes (2011) (10)
The novel monoamine reuptake inhibitor and potential antidepressant, S33005, induces Arc gene expression in cerebral cortex. (2004) (10)
[35S]–GTPγS autoradiography reveals α2 adrenoceptor-mediated G-protein activation in amygdala and lateral septum (2000) (10)
The selective tachykinin neurokinin 1 (NK1) receptor antagonist, GR 205,171, stereospecifically inhibits light-induced phase advances of hamster circadian activity rhythms. (2005) (10)
Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo. (1995) (10)
Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with alpha/beta-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors. (2007) (10)
S 14671: a novel naphthylpiperazine 5-HT1A agonist of high efficacy and exceptional in vivo potency. (1991) (9)
Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist d-serine (2021) (9)
Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank. (2014) (9)
LY2033298, a positive allosteric modulator at muscarinic M4 receptors, enhances inhibition by oxotremorine of light-induced phase shifts in hamster circadian activity rhythms (2012) (9)
Positive allosteric modulators at GABAB receptors exert intrinsic actions and enhance the influence of baclofen on light-induced phase shifts of hamster circadian activity rhythms (2011) (8)
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action (2022) (8)
P.2.d.009 Cellular and molecular mechanisms underlying increased adult hippocampal neurogenesis induced by agomelatine (2008) (8)
Corticotropin‐releasing factor receptor 2‐deficiency eliminates social behaviour deficits and vulnerability induced by cocaine (2018) (8)
Partial agonist actions at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation. (2008) (8)
Antagonists at the NMDA recognition site and blockers of the associated ion channel induce spontaneous tail-flicks in the rat. (1991) (8)
The Tetrahydroisoquinoline Derivative SB 269 , 652 Is an Allosteric Antagonist at Dopamine D 3 and D 2 Receptors (2010) (8)
Improvement in the selectivity and metabolic stability of the serotonin 5-HT(1A) ligand, S 15535: a series of cis- and trans-2-(arylcycloalkylamine) 1-indanols. (2002) (7)
CRF1 receptor-deficiency induces anxiety-like vulnerability to cocaine (2014) (7)
Erratum to “The novel monoamine reuptake inhibitor and potential antidepressant, S33005, induces Arc gene expression in cerebral cortex” [Eur. J. Pharmacol. 489 (2004) 179–185] (2004) (7)
Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol (2000) (7)
P.3.057 Stimulation of serotonin (5-HT)1A autoreceptors enhances dopamine (DA) and noradrenaline (NAD) release in rat frontal cortex: influence of S 15535, WAY 100,635 and 8-OH-DPAT (1996) (7)
Constitutive activity at serotonin 5-HT(1D) receptors: detection by homologous GTPgammaS versus [(35)S]-GTPgammaS binding isotherms. (2001) (7)
Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: improvements of affinity and selectivity for D3 versus D2 receptors. (2009) (7)
Stress reactions and endorphinergic systems. (1982) (7)
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine (2000) (7)
Novel Benzopyrano[3,4‐c]pyrrole Derivatives as Potent and Selective Dopamine D3 Receptor Antagonists. (1999) (7)
Blockade of α2-adrenoceptors induces Arc gene expression in rat brain in a glutamate receptor-dependent manner: A combined qPCR, in situ hybridisation and immunocytochemistry study (2012) (7)
Impaired working memory, cognitive flexibility and reward processing in mice genetically lacking Gpr88: Evidence for a key role for Gpr88 in multiple cortico‐striatal‐thalamic circuits (2020) (7)
Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT6 receptor ligands with significant selectivity for D3 over D2 receptors. (2017) (7)
Pindolol antagonises G-protein activation at both pre- and postsynaptic serotonin 5-HT1A receptors: a [35S]GTPγS autoradiography study (2001) (6)
acetamide ) , a Preferential Dopamine D 3 versus D 2 Receptor Antagonist and Potential Antipsychotic Agent : III . Actions in Models of Therapeutic Activity and Induction of Side Effects (2007) (6)
TAAR1-Dependent and -Independent Actions of Tyramine in Interaction With Glutamate Underlie Central Effects of Monoamine Oxidase Inhibition (2020) (6)
Linking Stress and Schizophrenia: A Focus on Prepulse Inhibition (2011) (6)
Benzamides derived from 1,2-diaminocyclopropane as novel ligands for human D2 and D3 dopamine receptors. (2000) (6)
Dysbindin‐1 modifies signaling and cellular localization of recombinant, human D3 and D2 receptors (2016) (6)
P.1.c.014 The novel antidepressant, agomelatine, blocks cerebral 5-HT2C receptors in vivo: a phMRI challenge study in rats (2009) (6)
P.2.d.006 Effects of agomelatine and S32006, a selective 5-HT2C receptor antagonist, in chronically-stressed tree shrews (2008) (6)
P.1.047 Yohimbine is a potent, partial agonist at rat and cloned, human serotonin1A receptors: A comparison to buspirone and its metabolite, 1-pyrimidinylpiperazine (1997) (6)
Endorphins and nociception: an overview. (1982) (5)
Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists. (2014) (5)
Knock-Down of GPR88 in the Dorsal Striatum Alters the Response of Medium Spiny Neurons to the Loss of Dopamine Input and L-3-4-Dyhydroxyphenylalanine (2019) (5)
Effects of systemically applied nAChRα7 agonists and antagonists on light-induced phase shifts of hamster circadian activity rhythms (2014) (5)
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia (2020) (5)
Trace Amine-Associated Receptor 1 Contributes to Diverse Functional Actions of O-Phenyl-Iodotyramine in Mice but Not to the Effects of Monoamine-Based Antidepressants (2021) (5)
Serotonin 2 C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats : distinct effects of agonists and inverse agonists in a rat model of Parkinson ’ s disease (2013) (5)
Parkinson’s disease and light: The bright and the Dark sides (2019) (5)
P62 accumulates through neuroanatomical circuits in response to tauopathy propagation (2021) (5)
8-OH-DPAT-induced corticosterone secretion as an in vivo model of 5-HT1A receptor function (1990) (5)
Parallel evaluation of 5-HT1A receptor localization and functionality: autoradiographic studies with [35S]-GTP gamma S and the novel, selective radioligand, [3H]-S 15535. (1998) (5)
Opioids II (1993) (5)
Induction of spontaneous tail-flicks in rats by blockade of transmission at N-methyl-D-aspartate receptors: roles of multiple monoaminergic receptors in relation to the actions of antipsychotic agents. (2000) (5)
Multiple opioid systems and pain: new directions (1990) (4)
Ligand modulation of [35S]GTPgammaS binding at human alpha(2A), alpha(2B) and alpha(2C) adrenoceptors. (2002) (4)
Characterization of Potent and Selective Antagonists at Postsynaptic 5- HT1A Receptors in a Series of N4-Substituted Arylpiperazines. (1996) (4)
Synthesis and binding studies on a new series of arylpiperazino benzazol-2-one and benzoxazin-3-one derivatives as selective D4 ligands. (2000) (4)
Distinctive binding properties of the negative allosteric modulator, [3H]SB269,652, at recombinant dopamine D3 receptors (2018) (4)
IS ß-ENDORPHIN INVOLVED IN THE ANALGESIA GENERATED BY STRESS? (1980) (4)
ACTIONS OF SELECTIVE ANTAGONISTS AT SEROTONIN (5‐HT)2A, 5‐HT2B AND 5‐HT2C RECEPTORS IN RODENT MODELS OF POTENTIAL ANXIOLYTIC PROPERTIES (1998) (4)
The serotonin (5-HT)1A agonist, LY 165,163, induces contralateral rotation in unilateral substantia nigra-lesioned rats via dopamine receptors (1991) (4)
A Subset of Purposeless Oral Movements Triggered by Dopaminergic Agonists Is Modulated by 5-HT2C Receptors in Rats: Implication of the Subthalamic Nucleus (2020) (4)
Lack of evidence for a role of endorphinergic mechanisms in mediating a discriminative stimulus produced by diazepam in rats (2004) (3)
PROTEOMIC AND FUNCTIONAL ANALYSIS SUGGESTS THAT 5-HT6 RECEPTORS COMPROMISE COGNITION BY RECRUITING MTOR (2010) (3)
[(35)S]-GTPgammaS autoradiography reveals alpha(2) adrenoceptor-mediated G-protein activation in amygdala and lateral septum. (2000) (3)
TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP-363856 (2022) (3)
Endogenous Opioid Systems in the Control of Pain (1991) (3)
CRF1 but not glucocorticoid receptor antagonists reduce separation-induced distress vocalizations in guinea pig pups and CRF overexpressing mouse pups. A combination study with paroxetine (2017) (3)
P.1.221 Actions of the selective melanin concentrating hormone1 receptor antagonist, (+)SNAP-7941, in models of potential antidepressant and anxiolytic activity in rodents (2003) (3)
Modification of nociception in a model of localized inflammatory pain by long-term administration of naloxone. (1990) (3)
Glutamatergic and dopaminergic modulation of cortico-striatal circuits probed by dynamic calcium imaging of networks reconstructed in microfluidic chips (2018) (2)
LY2033298, a positive allosteric modulator at muscarinic M4 receptors, enhances inhibition by oxotremorine of light-induced phase shifts in hamster circadian activity rhythms (2012) (2)
Contrasting influence of triazolo-benzodiazepines as compared with benzodiazepines upon dialysate levels of noradrenaline, dopamine and serotonin in frontal cortex of freely-moving rats (2001) (2)
Antipsychotic profile of the novel benzopyranopyrrole and preferential dopamine D3 receptor antagonist, S33138 (2002) (2)
Chapter 6.1 The role of microdialysis in drug discovery: focus on antipsychotic agents (2006) (2)
P.2.d.009 Agomelatine, a novel pharmacological approach to treating depression (2006) (2)
P-4-12 In vitro and ex vivo patterns of occupation of 5-HT2A and α1-adrenergic as compared to dopamine D2 receptors by novel antipsychotics (1995) (2)
S33138 N -[4-[2-[(3 aS ,9 bR )-8-Cyano-1,3 a ,4,9 -tetrahydro[1]-benzopyrano[3,4- a Preferential Dopamine D 3 versus D 2 Receptor Antagonist and Potential Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral Characterization in Vivo (2008) (2)
Pimozide blocks the open-field hyperactivity produced by lesions of the ventral noradrenergic bundle in rats (1984) (2)
[Dopamine D3 receptors as a novel target for improving the treatment of schizophrenia]. (2005) (2)
Stereoselective and region-specific induction of immediate early gene expression in rat parietal cortex by blockade of neurokinin 1 receptors (2006) (2)
Design, Synthesis and Structure—Activity Relationships of Novel Strychnine-Insensitive Glycine Receptor Ligands. (1999) (1)
Anxiolytic profile of S 16924, a novel antipsychotic possessing marked serotoni (5-HT)1A receptor agonist properties (1997) (1)
A novel in vivo model of 5-HT1A function in the rat: 8-OH-DFAT-induced spontaneous tail-flicks (1990) (1)
Validation of the Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) questionnaire for adults (2022) (1)
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing (2020) (1)
Novel in vivo Models of 5-HT 1A Receptor-Mediated Activity: 8-OH-DPAT-induced Spontaneous Tail-Flicks and Inhibition of Morphine-Evoked-Antinociception (1991) (1)
ALLOSTERIC MODULATION OF MUSCARINIC M4 RECEPTORS IN THE TREATMENT OF SCHIZOPHRENIA: A PHARMACOLOGICAL COMPARISON OF LY2033298 VS VU0152099 (2010) (1)
S.12.02 Absence of D-serine results in abnormal dopamine–glutamate dialogue in the prefrontal cortex (2014) (1)
COMMON FUNCTIONAL CORRELATES OF NMDA RECEPTOR ANTAGONISM AND 5??? HT1A RECEPTOR AGONISM: INDUCTION OF SPONTANEOUS TAIL-FLICKS BY NMDA ANTAGONISTS AND CHANNEL BLOCKERS VIA A SPINAL LOCUS INDEPENDENT OF 5-HT NEURONES (1992) (1)
The novel monoamine reuptake inhibitor and potential antidepressant, S33005, induces Arc gene expression in cerebral cortex. (2004) (1)
Specific Mutations in the Cholesterol-Binding Site of APP Alter Its Processing and Favor the Production of Shorter, Less Toxic Aβ Peptides (2022) (1)
Central mechanisms of pain control: a survey (1987) (1)
Benzopyran derivatives, their preparation and pharmaceutical compositions containing them (1995) (1)
Prospects for improved prevention and treatment of neuropsychiatric disorders: Neuroscience Applied (2022) (1)
Indanyl-piperazine derivatives, to processes for their preparation and pharmaceutical compositions containing them (2006) (1)
P.1.005 Mutating the cholesterol binding site on amyloid precursor protein alters the processing and production of Aβ-amyloid peptides (2018) (1)
OPPOSITE MODULATION OF 5-HT1A RECEPTOR-MEDIATED SPONTANEOUS TAIL- FLICKS BY, AND, RECEPTORS: INTRINSIC ANTAGONISM OF. RECEPTORS MASKS AGONIST PROPERTIES OF 5-HT1A ???PARTIAL AGONISTS??? (1992) (1)
P-4-13 Comparative profiles of interaction of atypical antipsychotics at cloned human dopamine hD2, hD3 and hD4 receptors: S 16924 shows a marked preference for hD4 sites (1995) (1)
Alpha 2-adrenergic mechanisms of analgesia: strategies for improving their therapeutic window and identification of the novel, potent alpha 2A-adrenergic receptor agonist, S 18616. (1998) (1)
P.2.b.006 Allosteric modulation of GABAB receptor coupling in rat brain: G-protein subtype dependence revealed by immunocapture scintillation proximity assays (2006) (1)
P.1.023 Dopamine D2, D3 and D4 receptors and depression: Actions of selective ligands in the forced swim model of potential antidepressant properties in rats (1997) (1)
The novel, potential antidepressant agents, S35966 and S 35967, interact both with alpha2-adrenoceptors and with serotonin and norepinephrine transporters (2001) (1)
DISCRIMINATIVE STIMULUS (DS) PROPERTIES OF THE NOVEL AND POTENT SEROTONIN (5‐HT)2C RECEPTOR AGONIST, RO 60–0175, IN RATS (1998) (1)
Faculty Opinions recommendation of Tau kinetics in neurons and the human central nervous system. (2018) (1)
Cromenicos new derivatives, their preparation process and pharmaceutical compositions containing them. (1998) (0)
Use of agomelatine for obtaining medicaments intended for the treatment of obsessive compulsive disorder (OCD) (2010) (0)
New derivatives of benzo [3,4] cyclobuta [1,2-c] pyrrole, their process for the preparation and pharmaceutical compositions containing them (1999) (0)
New 1,4-disubstituted piperazine (1991) (0)
P.1.007 Ketamine-induced plasticity in mouse-primary and human-iPSC-derived dopaminergic neurons involves D3R and mTOR pathway (2016) (0)
Functional interrelationships amongst serotonergic, adrenergic and dopaminergic pathways in frontal cortex: Significance for the actions of antidepressant agents (2001) (0)
S.12.02 A human pluripotent stem cell-derived neuronal model for characterisation of pathways regulating the autism and schizophrenia-related gene SHANK-3 (2015) (0)
Use of agomelatine, to achieve targeted medicine to treat general anxiety disorders (2007) (0)
P.1.007 A proteomic and functional analysis reveals that 5-HT6 receptors modulate neuronal differentiation by recruitment of Cdk5 (2013) (0)
New indoline derivatives, method of preparing them and pharmaceutical compositions containing them (2002) (0)
P.3.d.017 Agonist-dependent internalization of 5-HT6 receptors visualized by immunofluorescence assay: blockade by antipsychotics (2008) (0)
New spiroimidazoliniques derivatives, method of preparing them and pharmaceutical compositions containing them (1998) (0)
Faculty Opinions recommendation of Genetic heritability and shared environmental factors among twin pairs with autism. (2011) (0)
New chromeniques derivatives, method of preparing them and pharmaceutical compositions containing them (1997) (0)
P.2.002 Positive allosteric modulation of metabotropic glutamate 5 receptors prevents and reverses social discrimination deficits in rats (2012) (0)
Lipid Dys-Homeostasis Contributes to APOE4-Associated AD Pathology (2022) (0)
New compounds n-aryl piperidine, their process for the preparation and pharmaceutical compositions containing them (1997) (0)
S.24.04 Cognitive deficits of schizophrenia and their control by the mTOR pathway (2015) (0)
P.1.h.009 Local inactivation of G protein-coupled receptor 88 restores motor and cognitive functions impaired in a rat model of schizophrenia (2014) (0)
the Medulla of Neurons in Superficial and Deeper Dorsal Horn of -Adrenoceptors Modulate NMDA-Evoked Responses (2015) (0)
Diphenylharnstoffderivate and their use as alpha2 / 5-HT2c antagonists (2001) (0)
P-11-6 Stereospecific modulation of the electrical activity of ascending dopaminergic as compared to serotoninergic pathways by preferential agonists and antagonists at dopamine D3 receptors (1995) (0)
Inverse Agonists and Serotonergic Transmission - Antagonist profile of SB-258719 (1999) (0)
Piperazine derivatives of their process for the preparation and pharmaceutical compositions containing them (2005) (0)
New derivatives of diphenyl, their process for the preparation and pharmaceutical compositions containing them (2000) (0)
Derivatives of benzo (1,2-c) pyrrole as inhibitors of serotonin resumption (2000) (0)
Novel compounds cyano-indoles serotonin reuptake inhibitors, their process for the preparation and pharmaceutical compositions containing them (1999) (0)
New Naphtalinderivate, their preparation process and the pharmaceutical compositions containing them (2007) (0)
P.3.060 A comparative in vitro and in vivo characterization of the novel dopamine D3 receptor antagonists, (+)S 14297, nafadotride, GR 103,691 and U 99,194 (1996) (0)
S.04.02 Recruitment of the mTOR complex 1 by 5-HT6 receptors: potential role in the cognitive deficits of schizophrenia (2012) (0)
Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine (2012) (0)
Novel compounds cyano-indoles serotonin reuptake inhibitors, and their method of preparing such pharmaceutical compositions containing them (1999) (0)
Benzodioxan derivatives, process for their preparation and pharmaceutical compositions containing them (1995) (0)
New trans-3,4,4a, 5,6,10b-hexahydro-2H-naphth [1,2-b] -1, 4-oxazine disubstituted their process for the preparation and pharmaceutical compositions containing them (1997) (0)
Mutations in the juxtamembrane segment of the cholesterol-binding site of APP alter its processing and promotes production of shorter, less toxic Aβ peptides (2020) (0)
1,4-Disubstituted piperazines for the treatment of disorders of the central nervous system and by diseases nervenendokrinen (1993) (0)
An agonist action at 5-HT1A receptors functionally antagonises opioid antinociception in rodents (1990) (0)
P.106 Induction of aggregation by tau seeding in tauP301S-PS19 transgenic mice (2020) (0)
New naphthalenic derivatives, process for their preparation and pharmaceutical compositions containing them. (2007) (0)
New 4-one derivative of his process for the preparation and pharmaceutical compositions containing the (1995) (0)
Benzospiroalkenderivater, process for their preparation and to pharmaceutical compositions containing such (1994) (0)
Countering core and co-morbid symptoms of affective disorders: Complementary multi-target strategies (2006) (0)
Actions of antipsychotic drugs at 5-HT-1C and 5-HT-2 receptors Evidence for potent 5-HT-1C receptor antagonism by clozapine but not haloperidol both in vitro and in vivo (1993) (0)
Erratum: Stereoselective and region-specific induction of immediate early gene expression in rat parietal cortex by blockade of neurokinin 1 receptors (Journal of Psychopharmacology (2006) 20 (570-576) DOI: 10.1177/ 0269881105059327) (2011) (0)
New bentsodioksaaniyhdisteet, a process for their preparation and to pharmaceutical compositions containing them (1995) (0)
Lifelong CRF overproduction is associated with altered gene expression and sensitivity of discrete GABAA and mGlu receptor subtypes (2011) (0)
P.2.02 Quantification of corticosterone and corticotropin releasing factor in amygdala dialysates: modulation by stress (2009) (0)
P.1.g.044 Trace amine-associated receptor 1 inhibits a hyperglutamatergic state induced by dopamine deficiency (2014) (0)
INTERACTION OF 5-HT. AGONISTS AND ANTAGONISTS AT ADRENOCEPTORS IN THE RAT: CHARACTERIZATION WITH PROPOSED IN VIVO MODELS OF ??1A- AND ??2A -MEDIATED ACTIVITY (1992) (0)
New tetracyclic compounds 1,4-oxazine, their process for the preparation and pharmaceutical compositions containing them (1995) (0)
Derivatives benzo- (3,4-cyclobutane-1,2-c) pyrrole, their preparation process and pharmaceutical compositions containing them. (2000) (0)
Use of agomelatine to obtain medication for the treatment of generalized anxiety disorder. (2007) (0)
S.07.01 Quantification of corticosterone and corticotrophin releasing factor in amygdala dialysates: modulation by stress (2009) (0)
Novel compounds of 2-aminoindan, process for their preparation and pharmaceutical compositions containing them (1998) (0)
Cyanoindole derivatives as inhibitors of the reuptake of serotonin, processes for their preparation and pharmaceutical compositions containing them (2000) (0)
New benzopyran derivatives, their preparation process and pharmaceutical compositions containing them. (1995) (0)
Use of agomelatine for the preparation of medicaments for the treatment of generalized anxiety disorder (2007) (0)
Tetracyclic 1,4-oxazinderivater, process for their preparation and to pharmaceutical preparations which contain dis (1995) (0)
New compounds of benzocyclobutane, their process for the preparation and pharmaceutical compositions containing them (1998) (0)
Subject Index Vol. 35, 1982 (1982) (0)
The novel, highly-selective serotonin (5-HT)1A receptor ligand, S37245, is an anxiolytic with potential procognitive and antidepressive properties (2002) (0)
A40 NEUROKININ1 RECEPTOR ANTAGONISTS EXERT ANXIOLYTIC PROPERTIES IN THE GERBIL SOCIAL INTERACTION TEST AND BLOCK THE ANXIOGENIC ACTION OF CITALOPRAM (2005) (0)
Amines novel compounds of the 6,7,8,9-tetrahydro-cyclopenta [a] naphthalene and 2,3-dihydro-cyclopenta [e] indene, their process for the preparation and pharmaceutical compositions containing them (1997) (0)
P.1.016 Modulation of dopamine D2L and D3 receptor signalling and cell surfacecytosol trafficking by dysbindin in CHO cells (2013) (0)
Benzo-dioxane, their preparation process and pharmaceutical compositions containing them. (1995) (0)
S.24.01 mTOR controls structural plasticity of dopaminergic neurons: implication in the actions of ketamine (2015) (0)
P62 accumulates through neuroanatomical circuits in response to tauopathy propagation (2021) (0)
CRF1 receptor-deficiency induces anxiety-like vulnerability to cocaine (2014) (0)
Faculty Opinions recommendation of Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice. (2021) (0)
New compounds of 2-amino indane, their process for the preparation and pharmaceutical compositions containing them (1997) (0)
Derivatives of benzo [3,4] cyclobuta [1,2-c] pyrrole as inhibitors of serotoningenindfangning (2000) (0)
New derivatives of indole carboxamide cyclobuta, their process for the preparation and pharmaceutical compositions containing them (2000) (0)
Derived from indanyl piperazines, their process for the preparation and pharmaceutical compositions containing them (2005) (0)
P.1.006 Stimulation of D3 receptors activates Akt/GSK-3beta and mTOR signalling pathways in nucleus accumbens and striatum (2012) (0)
New compounds of piperazine, piperidine and 1,2,5,6-tetrahydropyridine, their process for the preparation and pharmaceutical compositions containing them (1995) (0)
New bentsodioksaaniyhdisteet, a method for their preparation and pharmaceutical compositions containing them (1995) (0)
Comparison of the actions of Neurokinin1 (NK1) receptor antagonists in gerbils, guinea‐pigs and mice (2006) (0)
Faculty Opinions recommendation of miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. (2011) (0)
Chromium derivatives, processes for their preparation and pharmaceutical compositions containing them (1998) (0)
New derivatives of pyridine, their process for the preparation and pharmaceutical compositions containing them (1999) (0)
Aminomethylheterozyclischederivate, processes for their preparation and pharmaceutical compositions containing them (1997) (0)
P.1.008 V1B/CRF1 receptor heterodimerisation as a key mechanism of vasopressin and corticotropin-releasing factor synergism (2013) (0)
P.1.005 Glutamatergic and dopaminergic modulation of corticostriatal networks reconstructed in microfluidic chips (2017) (0)
Indane-1-ol derivatives, processes for their preparation and pharmaceutical compositions containing them (1999) (0)
BENZODIOXEPIPERAZINE DERIVATIVES AS NOVEL 5-HT1A ANTAGONISTS: A PHARMACOLOGICAL EVALUATION OF THEIR SELECTIVITY AND PURITY (1992) (0)
D-serine governs NMDA receptors-dependent synaptic activity in the prefrontal cortex of adult rats. (2009) (0)
INFLUENCE OF PSYCHOSTIMULANTS UPON LOCOMOTOR ACTIVITY AND MONOAMINERGIC TRANSMISSION IN TRACE AMINE ASSOCIATED RECEPTOR1 KNOCKOUT MICE (2008) (0)
Indanol derivatives, processes for their preparation and pharmaceutical compositions containing them (1998) (0)
P.1.g.093 Ketamine promotes plasticity in mouse-primary and human-iPSC-derived dopaminergic neurons via D3R and mTOR signalling (2016) (0)
Imidazoliniques new compounds, their process for the preparation and pharmaceutical compositions containing them (1998) (0)
New heterocyclic derivatives aminomethyl, their process for the preparation and pharmaceutical compositions containing them (1996) (0)
Heterocyclic tertiary amines, their preparation process and pharmaceutical compositions containing them. (1996) (0)
Antidepressant effects of agomelatine in the olfactory bulbectomised rat : A comparison with melatonin and the 5-HT2C receptor antagonist, S32006 (2010) (0)
Indan-1-ol derivatives, process for their preparation and pharmaceutical compositions containing the derivatives (1999) (0)
Faculty Opinions recommendation of Expression-based drug screening of neural progenitor cells from individuals with schizophrenia. (2018) (0)
New compounds of the indanol, method of preparing them and pharmaceutical compositions containing them (1997) (0)
Interaction of the preferential D3 agonist (+)PHNO with dopamine D3-D2 receptor heterodimers and diverse classes of monoamine receptors: Relevance for PET imaging. (2022) (0)
New tetracyclic piperidine and 1,4-oxazine (1995) (0)
P.1.01 Time-dependent progression of tauopathy and disruption of synaptic proteins in the PS19 P301S transgenic mouse (2019) (0)
P.4.019 Absence of D-serine results in abnormal dopamine–glutamate dialogue in the prefrontal cortex (2014) (0)
S.27.04 Multiple dopamine receptors and cognitive function: focus on D3 vs D2 sites, the frontal cortex and schizophrenia (2008) (0)
New derivatives of 3- (piperid-4-yl) 1,2-benzisoxazole and 3- (piperazin-4-yl) 1,2-benzisoxazole, processes for their preparation and pharmaceutical compositions containing them (1996) (0)
Tetracyclic derivatives of the 1,4-oxazine, their preparation process and pharmaceutical compositions containing them. (1995) (0)
Indanolforbindelser, process for their preparation and to pharmaceutical compositions containing them (1998) (0)
1,4-Disubstituted piperazines, processes for their preparation and pharmaceutical compositions containing. (1991) (0)
PRO-COGNITIVE EFFECTS OF METABOTROPIC GLUTAMATE RECEPTOR (MGLUR)2/3 AND 5 AGONISTS IN RATS: A COMPARISON TO GLYCINEB/NMDA RECEPTOR MODULATORS (2010) (0)
S.01.02 Proteomics and phosphoproteomics for understanding cellular signalling and its disruption in CNS disorders (2014) (0)
New derivatives of benzoindoline, their process for the preparation and pharmaceutical compositions containing them (2003) (0)
Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management (2020) (0)
NOVEL OF INDANE-1-ol, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM (1998) (0)
S 18327, a novel phenylimidazolinone and potential antipsychotic: Antagonist properties at α2-adrenergic (AR) receptors in vitro and in vivo (1999) (0)
Use of agomelatine for obtaining medicaments intended for the treatment of Generalized Anxiety Disorder (2006) (0)
Correction To: TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP- 363856 (2022) (0)
New piperazine derivatives, piperidine and 1,2,5,6-tetrahydropyridine, their preparation process and pharmaceutical compositions containing them. (1996) (0)
A Molecular Basis for Selective Antagonist Destabilization of Dopamine D3 Receptor Quaternary Organization (2017) (0)
Erratum: The novel monoamine reuptake inhibitor and potential antidepressant, S33005, induces Arc gene expression in cerebral cortex (European Journal of Pharmacology (2004) 489 (179-185) DOI: 10.1016/j.ejphar.2004.03.002) (2004) (0)
Tetracyclic Analogues of (+)‐S 14297: Synthesis and Determination of Affinity and Selectivity at Cloned Human Dopamine D3 vs D2 Receptors. (1997) (0)
Benzocyklobutanforbindelser, process for their preparation and pharmaceutical compositions containing such compounds (1999) (0)
S.08.04 Dopamine D3 receptors as a target for the treatment of schizophrenia: contrasting actions of antipsychotic agents (2006) (0)
Benzozyclobutanverbindungen, their preparation method and pharmaceutical compositions containing them (1999) (0)
S28 NMDA RECEPTORS AND COGNITION: THE GLYCINE B CO-AGONIST SITE AS A TARGET FOR IMPROVING COGNITIVE PERFORMANCE IN SCHIZOPHRENIA? (2005) (0)
Pyrimidin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them (2002) (0)
P.288 Neuroregenerative and neuroprotective properties of dopamine D3 receptor agonists in human dopaminergic neurons derived from iPSC (2019) (0)
Faculty of 1000 evaluation for Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau. (2018) (0)
P.2.001 Local inactivation of the G proteincoupled receptor 88 attenuates behavioural deficits elicited by neonatal administration of phencyclidine in rats (2014) (0)
Diphenylurea derivatives and their use as alpha2 antagonists / 5-HT2C. (2001) (0)
New amino derivatives of 6,7,8,9-tetrahydro-cyclopenta (a) -naphthalene and 2,3-dihydro-cyclopenta (e) indene, their methods of preparation and pharmaceutical compositions containing them. (1998) (0)
INHIBITION OF DORSAL RAPHE NUCLEUS FIRING RATE BY 5‐HT1A LIGANDS: ARE PRE AND POST‐SYNAPTIC 5‐HT1A RECEPTORS IDENTICAL? (1992) (0)
Cyano-indoles as inhibitors of serotonin reuptake and ligands 5-HT2C receptor. (2000) (0)
Pyrimidin-4-one derivatives, to processes for their preparation and compositions containing them (2002) (0)
Faculty Opinions recommendation of AUTACs: Cargo-Specific Degraders Using Selective Autophagy. (2019) (0)
N-arylpiperidine derivatives and their use as ligands of the 5-HT1B. (1998) (0)
Dopamine D3 receptors: Functional significance and novel ligands as antipsychotic agents (2002) (0)
New benzodioxane compound, its production and medicinal composition containing the same (1995) (0)
Heterocyclic aminomethyl derivatives, process for their preparation and pharmaceutical compositions containing the derivatives (1997) (0)
New derivatives of pyrimidin-4-ones, their process for the preparation and pharmaceutical compositions containing them (2001) (0)
Neurons In Vitro and In Vivo Cortical NMDA-Mediated Responses in Rat Prefrontal Glycine Tranporter-1 Blockade Potentiates (2015) (0)
New benzopyrano [3,4-c] pyrrole, a process for their preparation and to pharmaceutical compositions containing them (1995) (0)
New derivatives of beta-carboline, their process for the preparation and pharmaceutical compositions containing them (1999) (0)
New compounds of the benzo-cyclobutane, their preparation process and pharmaceutical compositions containing them. (1999) (0)
Impaired working memory, cognitive flexibility and reward processing in mice genetically lacking Gpr88: evidence for a key role in Gpr88 in multiple cortico-striatal-thalamic circuits : GPR88 and cortico-striatal-thalamic circuits (2020) (0)
Piperazine derivatives and their use as inhibitors of serotonin reuptake or neurokinin antagonists. (2006) (0)
P.5.035 Characterization of [3H]GR 125,743 as a radioligand at 5-HT1Dreceptors in guinea pig brain: A comparison with [3H]5CT (1996) (0)
S.07.01 A proteomic and functional analysis reveals that 5-HT6 receptors modulate neuronal differentiation by recruitment of Cdk5 (2013) (0)
P.1.g.011 Ketamine and pramipexole promote structural plasticity in human iPSC-derived dopaminergic neurons via D3 receptor and mTOR pathway (2017) (0)

This paper list is powered by the following services:

Mark John Millan's Academic­Influence.com Rankings

Mark John Millan's Degrees

Similar Degrees You Can Earn

Why Is Mark John Millan Influential?

Mark John Millan's Published Works

Published Works

Mark John Millan's AcademicInfluence.com Rankings